Mirum Pharmaceuticals

MIRM

Market cap $3.69B

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Peetz - CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced i.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms raised their price targets following Q2 results.

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.